Toru M, Moriya H, Yamamoto K, Shimazono Y
Folia Psychiatr Neurol Jpn. 1976;30(2):153-64. doi: 10.1111/j.1440-1819.1976.tb00118.x.
The therapeutic effectiveness of sulpiride on various types of neurosis was compared with that of chlordiazepoxide on a double-blind basis. Global improvement, effectiveness on various types of neurosis, and side effects were studied for a period of two weeks. The subjects consisted of 41 males and 32 females. Neurosis including borderline case and vegetative dystonia was divided into eight different subtypes comprising borderline, neurasthenic state, hypochondria, obsessive neurosis or phobia, depressive neurosis, anxiety neurosis, vegetative dystonia, and others. A newly devised matched-pair method of comparison was employed to achieve even distribution of the eight subtypes of neurosis between the two drug groups. As a result 40 patients fell in the sulpiride group and 33 patients in the chlordiazepoxide group. The backgrounds of the paired patients matched closely. The daily dose was uniformly 150 mg for sulpiride and 30 mg for chlordiazepoxide in the first week but was raised (or lowered in some cases) to 225 mg and 45 mg, respectively, in the second week according to severity. The rate of global improvement was 79% for the sulpiride group and 90% for chlordiazepoxide group, and the difference did not reach statistical significance. Improvement by manifestation (13 symptom items) and type of neurosis also matched. Side effects occurred at a rate of 28% (sulpiride group) and 30% (chlordiazepoxide group), and also matched closely in incidence and variety. The authors concluded that sulpiride in appropriate doses is useful in the treatment of neurosis without causing extrapyramidal side effects.
在双盲基础上,比较了舒必利与氯氮卓对各类神经症的治疗效果。对整体改善情况、对各类神经症的疗效及副作用进行了为期两周的研究。受试者包括41名男性和32名女性。神经症(包括临界病例和植物神经功能障碍)被分为八个不同亚型,即临界型、神经衰弱状态、疑病症、强迫性神经症或恐惧症、抑郁性神经症、焦虑性神经症、植物神经功能障碍及其他类型。采用一种新设计的配对比较方法,以使两个药物组之间神经症的八个亚型分布均匀。结果,舒必利组有40例患者,氯氮卓组有33例患者。配对患者的背景紧密匹配。第一周舒必利的日剂量统一为150mg,氯氮卓为30mg,但在第二周根据病情严重程度分别提高(或在某些情况下降低)至225mg和45mg。舒必利组的整体改善率为79%,氯氮卓组为90%,差异无统计学意义。按症状表现(13个症状项目)和神经症类型的改善情况也相匹配。副作用发生率舒必利组为28%,氯氮卓组为30%,在发生率和种类上也非常接近。作者得出结论,适当剂量的舒必利可用于治疗神经症,且不会引起锥体外系副作用。